A new study finds that adding IL-5 inhibitors to standard steroid treatment for DRESS — a rare but serious drug reaction — helps patients taper off steroids faster and clear eosinophilia more quickly. Patients on the combo therapy also had fewer rebound symptoms and zero hospital readmissions, compared to 13% in the steroid-only group. The findings open the door to a steroid-sparing approach for this difficult-to-manage condition.
A rare but life-threatening drug reaction just got a potential new treatment ally. A retrospective study published in JAMA Dermatology found that patients with drug reaction with eosinophilia and systemic symptoms (DRESS) who received an IL-5 inhibitor (mepolizumab or benralizumab) alongside corticosteroids were able to taper and stop steroids significantly faster than those on steroids alone — and with fewer complications along the way.
DRESS is a severe cutaneous adverse reaction that can be tricky to manage, often requiring prolonged steroid courses that carry their own risks. In this study of 73 hospitalized adults across three Boston hospitals, those who received an IL-5 inhibitor also saw faster resolution of eosinophilia and had lower total steroid exposure overall.
By the Numbers:
Why it matters: DRESS has limited treatment options, and long-term steroid use carries significant side effects. These findings suggest IL-5 inhibitors could be a meaningful steroid-sparing tool — though cost and access remain real-world hurdles to widespread adoption.
